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g-Catenin is overexpressed in acute myeloid leukemia and
promotes the stabilization and nuclear localization of b-catenin
RG Morgan, L Pearn, K Liddiard, SL Pumford, AK Burnett, A Tonks1 and RL Darley1
Canonical Wnt signaling regulates the transcription of T-cell factor (TCF)-responsive genes through the stabilization and nuclear
translocation of the transcriptional co-activator, b-catenin. Overexpression of b-catenin features prominently in acute myeloid
leukemia (AML) and has previously been associated with poor clinical outcome. Overexpression of g-catenin mRNA (a close
homologue of b-catenin) has also been reported in AML and has been linked to the pathogenesis of this disease, however, the
relative roles of these catenins in leukemia remains unclear. Here we report that overexpression and aberrant nuclear localization of
g-catenin is frequent in AML. Signiﬁcantly, g-catenin expression was associated with b-catenin stabilization and nuclear localization.
Consistent with this, we found that ectopic g-catenin expression promoted the stabilization and nuclear translocation of b-catenin
in leukemia cells. b-Catenin knockdown demonstrated that both g- and b-catenin contribute to TCF-dependent transcription in
leukemia cells. These data indicate that g-catenin expression is a signiﬁcant factor in the stabilization of b-catenin in AML. We also
show that although normal cells exclude nuclear translocation of both g- and b-catenin, this level of regulation is lost in the majority
of AML patients and cell lines, which allow nuclear accumulation of these catenins and inappropriate TCF-dependent transcription.
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INTRODUCTION
Wnt signaling is an evolutionary conserved pathway critical for
normal developmental processes in both the embryo and adult,
including cell growth and differentiation.1 In the absence of
an external Wnt ligand, the canonical pathway is maintained in a
state of suppression through constitutive degradation of the
central mediator, b-catenin. This degradation is mediated through
a destruction complex consisting of CK-1, GSK-3b, axin-1 and APC,
which promotes its proteosomal degradation in the cytoplasm.
The canonical pathway becomes activated upon binding of an
exogenous Wnt ligand to the frizzled/lipoprotein receptor-related
protein family of receptors. Activation of these receptors leads to
the recruitment of disheveled, a failure of destruction complex
assembly and consequent stabilization of b-catenin. A second
requirement for canonical Wnt signaling is that b-catenin enters
the nucleus where it associates with members of the T-cell
factor (TCF)/LEF family of DNA-bound transcription factors on
TCF-binding elements to mediate activation of Wnt target genes,
such as c-myc and cyclin D1.1
Wnt signaling is known to be active in normal hematopoietic
development. The expression of multiple Wnt genes has been
identiﬁed in human hematopoiesis, and Wnt factors can
inﬂuence the proliferation and differentiation of hematopoietic
stem/progenitor cells (HSPCs).2 Despite these ﬁndings, it remains
controversial whether Wnt signaling is actually required for
hematopoiesis because catenin knockout studies have demon-
strated functional redundancy.3–5 Recently, it has been proposed
that canonical Wnt signaling is required for hematopoietic
stem cell (HSC) self-renewal but the level of signaling required
for normal HSC reconstitution is very low. In support of this,
conditional overexpression of a stabilized form of b-catenin in
murine models leads to a block in multilineage differentiation and
a transient expansion of the HSC pool, but also caused exhaustion
of long-term HSCs.6
Dysregulation of Wnt signaling has been reported in a
number of hematological malignancies, including chronic lym-
phocytic leukemia,7 chronic myelogenous leukemia8 and acute
lymphoblastic leukemia,9 and has been identiﬁed as one of the
key signaling networks dysregulated in acute myeloid leukemia
(AML).10 Speciﬁcally, overexpression of the key mediator,
b-catenin, has been identiﬁed in myeloid cell lines, as well
as primary AML blasts,11–15 where it has been associated with
poor survival.16–18 The role of b-catenin overexpression in the
pathogenesis of AML is unclear; however, it has previously been
associated with the establishment and maintenance of leukemia-
initiating cells.8,19,20 The close structural and functional
homologue of b-catenin, g-catenin (aka plakoglobin, JUP), has
also been found to be dysregulated in AML.21–23 Like b-catenin,
g-catenin is regulated by the same destruction complex and has
established roles in cell adhesion; however, its role as a
transcriptional activator of Wnt signaling is more contentious.24
Ectopic expression of g-catenin was found to accelerate the cell-
cycle progression of murine HSPC and to promote self-renewal
in vitro and leukemogenic capacity when transplanted in vivo.22
Despite these studies, there has been no systematic examination
of g-catenin expression (and corresponding analysis of b-catenin)
at the protein level in AML, which might indicate whether
g-catenin represents an alternative, or additional, mechanism
of transcriptional activation in AML. Here we have undertaken a
comprehensive analysis of cytosolic and nuclear expression of
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g- and b-catenin expression in AML and show that the expression
and translocation of these proteins is linked in this disease.
g-Catenin expression in the context of myeloid leukemia cells
promotes the stabilization of b-catenin and its nuclear
translocation, leading to increased TCF-dependent transcription.
We also show that the ability of g-catenin to inﬂuence b-catenin
expression is abnormal, because their expression is independently
regulated in HSPC. Further, although nuclear accumulation of both
catenins is not observed in normal HSPC, the majority of leukemia
cells allow the nuclear accumulation of g- and b-catenin and the
consequent activation of TCF-dependent transcription.
MATERIALS AND METHODS
Normal and AML patient cells
Peripheral blood mononuclear cells (MNCs) or bone marrow MNCs were
collected from AML patients enrolled in the UK Medical Research Council/
National Cancer Research Institute 10–15 AML clinical trials at point of
diagnosis; see Supplementary Table S1. Normal human CD34þ HSPCs
were isolated from cord blood MNC using MiniMACS (Miltenyi Biotec,
Bisley, UK). All samples were obtained with informed consent and with
approval from the South East Wales Research Ethics Committee in
accordance with the 1964 Declaration of Helsinki. MNCs used in this study
were separated on Ficoll-Hypaque (Sigma-Aldrich, Poole Dorset, UK) as
previously described.23
Retroviral transduction and ﬂow cytometric analysis
Normal human CD34þ HSPCs were retrovirally transduced with PINCO-
g-catenin (kindly provided by Martin Ruthardt22) on retronectin-coated
tissue culture plates as previously described.23 The leukemic cell lines K562,
U937, HEL and THP-1 (European Collection of Cell Cultures, Salisbury, UK)
were cultured as recommended and retrovirally transduced with pBabe-
puro g-catenin using a similar protocol as above. Prior to g-catenin
transduction, K562 and U937 cells were lentivirally transduced with the
b-catenin-activated reporter (BAR) system (kindly provided by RT Moon,
Washington, USA25). pBARVUbR contains a concatamer of 12 TCF response
elements upstream of a b-globin minimal promoter linked to Venus
(a variant of EYFP) and constitutively expresses DsRed as a selectable
marker. As a control for speciﬁcity, K562 cells were transduced with the
‘found unresponsive’ BAR (pfuBARVUbR) reporter, which contains mutated
TCF response elements. K562 cells overexpressing g-catenin were further
transduced with a lentivirus encoding b-catenin small hairpin RNA
(a gift from Bob Weinberg; Addgene plasmid 18803 (Cambridge, MA,
USA)). Catenin or control-transduced cell lines were assessed for TCF
reporter activity by ﬂow cytometric analysis. Cells expressing the BARV
reporter system (as identiﬁed by coexpression of DsRed marker) were
analyzed using the Accuri C6 cytometer (Accuri Cytometers, Ann Arbor, MI,
USA). Data analysis was performed using FCS Express version 4 (De Novo
Software, Los Angeles, CA, USA).
Assessment of catenin mRNA expression using quantitative
real-time PCR
See Supplementary Material.
Assessment of catenin protein expression using western blotting
Total protein lysates were prepared as previously described.26 Nuclear and
cytosolic protein fractions were prepared using a cell fractionation kit
(Biovision, Mountain View, CA, USA) according to the manufacturer’s
instructions. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
and electroblotting was performed as previously described26 using anti-g-
catenin (Clone 15; BD, Oxford, UK) or anti-b-catenin (Clone 14; BD). Equal
protein loading and purity of cytosolic/nuclear fractions was assessed
using anti-b-actin (mAbcam 8226; Abcam, Cambridge, UK), glyceraldehyde
3-phosphate dehydrogenase (6C5; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and histone H1 (AE-4; AbD Serotec, Kidlington, UK), respectively.
Densitometry was performed using Advanced Image Data Analyzer
software v4.5 (Raytek Scientiﬁc, Shefﬁeld, UK) and relative catenin levels
correlated using a Spearman’s coefﬁcient (R). Equivalent amounts of
cytosolic and nuclear protein were loaded for each patient sample and
catenin protein expression values were normalized to a standard loading
of K562 lysate. In some experiments, cells were treated for 16 h with 2.5mM
of the GSK inhibitor BIO ((2’Z,3’E)-6-Bromoindirubin-3’-oxime; Tocris, Bristol,
UK) prior to fractionation.
Assessment of g-catenin localization using confocal laser scanning
microscopy
AML MNCs or normal CD34þ HSPCs (up to 2 106) were ﬁxed in 2%
paraformaldehyde (Sigma-Aldrich) and permeabilised using 0.1% Triton
X-100, prior to 30min incubation with IgG2a monoclonal anti-g-catenin
antibody (M111; Abcam). Subsequently, cells were incubated with
monoclonal rat anti-mouse-IgG2a-FITC (LO-MG2a-9; AbD Serotec) for
30min at 4 1C. Cells were ﬁnally suspended in FACSFlow (BD) containing
165 nM TO-PRO-3 iodide (Invitrogen, Paisley, UK) and analyzed using
DMIRBE2 light microscope (Leica, Buckinghamshire, UK). Confocal immu-
noﬂuorescence was analyzed using the resonant scanning head of a TCS
SP2 confocal laser microscope (Leica) with a  63 oil immersion objective
NA 1.32 (HCX-PL-APO). The threshold for catenin ﬂuorescence was
determined using isotype-matched primary control antibodies. Z-sections,
exhibiting representative cytosolic and nuclear areas, were collected for 50
cells per patient and post-acquisition analysis of g-catenin localization was
performed using Leica confocal software ‘Lite’ version.
Statistical analyses
Signiﬁcance of difference using the Student’s t-test, and strength of
correlation using a Spearman’s or Pearson’s coefﬁcient (R), were performed
using GraphPad Prism v5.01 (GraphPad Software, Inc., San Diego, CA, USA).
RESULTS
g-Catenin protein is frequently overexpressed in AML
Previously, we have shown g-catenin mRNA to be frequently
overexpressed in AML patients,23 however, g-catenin expression is
also regulated at the protein level via the axin–CK-1–GSK3b–APC
complex.24 Therefore, we examined whether there was evidence
of g-catenin overexpression at the protein level and whether this
correlated with g-catenin mRNA expression in AML patients.
We characterized g-catenin expression in 44 AML patients
(Cohort 1 of Supplementary Table S1 and S2). g-Catenin protein
expression in AML blasts exhibited a multiple banding
pattern (Figure 1a), which has been observed previously for
b-catenin13,16,27 and is attributed to posttranslational
modiﬁcations.11,28 This pattern was found to be identical
regardless of antibody used for detection (Supplementary Figure
S1) and was also observed when g-catenin was ectopically
expressed (see below). Expression of g-catenin was found to be
highly heterogeneous, being undetectable in 20% (9/44) of
patients and overexpressed in 18% (8/44) of patients relative to
normal CD34þ HSPC (Figure 1b). This frequency of overexpression
was much lower than that observed at the mRNA level from our
previous analysis (62%; 114/184).23 We observed no correlation
with French–American–British type and no preferential over-
expression of g-catenin in the small number of patients assayed
(4/44) with core-binding factor abnormalities, which have
previously been reported to have high g-catenin mRNA.21,23
To better understand the mechanism of g-catenin overexpres-
sion in AML blasts (that is, transcriptional vs post-transcriptional),
we correlated mRNA and protein levels in these patients. Though
we found correlation of mRNA and protein levels for some
patients, we also observed patients that displayed high protein
levels despite of low mRNA expression and, conversely, patients
with high mRNA but low levels of protein (Figure 1c). Overall, this
resulted in a poor correlation (R¼ 0.18, n¼ 30). These data
suggest that although mRNA level may be inﬂuential, g-catenin
protein expression is strongly affected by post-transcriptional
mechanisms.
g-Catenin is aberrantly localized in AML
g-Catenin serves functions in both the cytoskeleton and in
transcriptional control in the nucleus, therefore subcellular
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location can act as an indicator of how g-catenin functions in AML.
We therefore examined the subcellular localization of g-catenin
protein in both normal CD34þ HSPC and primary AML patient
blasts. Using nuclear/cytosolic fractionation and western blotting
of 59 AML patients (cohort 2 of Supplementary Tables S1 and S3),
nuclear-localized g-catenin was found at very low levels in normal
CD34þ HSPC (Figure 2a). In contrast, 35/59 (59%) of AML patients
exhibited signiﬁcantly higher levels of nuclear-translocated
g-catenin, an observation conﬁrmed by confocal analysis
(Figure 2b, Supplementary Figure S3 and Supplementary Table
S4). Furthermore, nuclear g-catenin was found to correlate
(R¼ 0.57, Po0.0001) with corresponding cytosolic expression
level in AML blasts (Figure 2c). High levels of nuclear g-catenin
were also observed in patients with normal cytosolic levels,
therefore the frequency of aberrant nuclear localization of
g-catenin was much higher than its frequency of overexpression
(59% vs 18%). These data suggest that although nuclear
localization of g-catenin is not observed in normal HSPC, it readily
accumulates in the nuclei of AML blasts.
g-Catenin protein expression correlates with that of b-catenin in
AML blasts
The data above demonstrate stabilization of g-catenin protein
independent of mRNA expression level, suggesting in many
patients that this resulted from post-transcriptional dysregulation.
Because both g-catenin and b-catenin protein stability is regulated
by the destruction complex, this implies that patients over-
expressing g-catenin may also overexpress b-catenin. This could
arise either because a defect in the degradation complex might
mutually stabilize these proteins (as observed in colon cancer29)
and/or because high levels of g-catenin may saturate the
destruction complex indirectly stabilizing b-catenin.30 To assess
this, we reanalysed the cohort above for nuclear and cytosolic
levels of b-catenin. Given the structural homology shared between
g- and b-catenin molecules,31 we ﬁrst conﬁrmed no cross-
reactivity between the respective antibodies before such
analyses were performed (data not shown). We determined
whether, like g-catenin, b-catenin protein expression was
independent of mRNA level. This proved to be the case
(R¼ 0.23, n¼ 30; data not shown), suggesting that b-catenin
protein levels are also predominantly post-transcriptionally
regulated. We also found b- and g-catenin mRNA levels
correlated poorly (R¼ 0.27, n¼ 30). On the other hand, we
found a close correlation between g- and b-catenin protein
expression in AML blasts (R¼ 0.51, Po0.01; Figures 3a and b,
Supplementary Table S5). Furthermore, as with g-catenin (R¼ 0.57,
Po0.0001), we also observed a signiﬁcant correlation between
b-catenin expression and its nuclear localization (R¼ 0.56,
Po0.001; Figure 3c). These data suggest that, like g-catenin,
b-catenin protein expression in AML cells is heavily inﬂuenced by
post-transcriptional processes and that g- and b-catenin are
mutually stabilized and translocated to the nucleus in these cells.
Ectopic g-catenin expression stabilizes b-catenin in AML blasts but
not in normal cells
To establish whether the correlation between g- and b-catenin
protein expression observed in primary AML blasts was function-
ally driven, we examined the effect of ectopic g-catenin expression
on b-catenin level and the localization in both normal CD34þ
HSPC cells and leukemia cell lines. Ectopic expression of g-catenin
in CD34þ HSPC did not promote nuclear localization of this
protein, nor did it inﬂuence the expression or nuclear transloca-
tion of b-catenin, suggesting that in normal human hematopoietic
cells, the translocation and expression of these proteins is tightly
and independently regulated (Figure 4). We next examined the
effect of ectopic g-catenin overexpression in four myeloid
leukemia cell lines. In all the cell lines, except U937 cells, ectopic
expression of g-catenin promoted its nuclear localization
Figure 1. g-Catenin protein is frequently overexpressed in AML blasts. (a) Representative western blot data showing g-catenin (g-Cat) protein
expression in AML patient blast samples and normal CD34þ HSPC. K562 lysate was used to standardize the analysis. (b) Summary of g-catenin
fold overexpression in AML blasts (n¼ 44) relative to normal CD34þ HSPC (n¼ 3). Bars represent the mean expression from each cohort; the
dashed bar represents the threshold of g-catenin overexpression (mean of normal HSPCþ 2 s.d.). (c) Correlation between g-catenin mRNA
expression (derived from a validated Affymetrix probeset (Santa Clara, CA, USA); see Supplementary Figure S2) and g-catenin protein
expression (arbitrary densitometric units; see Materials and Methods) in AML blasts (n¼ 30).
g-Catenin dysregulation in AML
RG Morgan et al
338
Leukemia (2013) 336 – 343 & 2013 Macmillan Publishers Limited
Figure 2. g-Catenin subcellular localization is dysregulated in AML blasts. (a) Representative western blot data showing subcellular localization
(C, cytosolic and N, nuclear) of g-catenin protein in normal CD34þ HSPC and AML blasts. Actin and histone H1 (Hist H1) show relative protein
loading and fraction purity. (b) Representative examples of confocal laser scanning microscopy Z-sections demonstrating the subcellular
localization of g-catenin immunofluorescence within normal CD34þ HSPC and AML patient blasts (original magnification  63). Color-merged
images showing nuclear localization are shown in Supplementary Figure S3. (c) Summary data showing the correlation between cytosolic
g-catenin and nuclear g-catenin protein expression within AML blasts (n¼ 59; arbitrary densitometric units). The dashed lines represent the
threshold of g-catenin overexpression for nuclear and cytosolic fractions (mean of normal HSPCþ 2 s.d.).
Figure 3. g-Catenin protein expression correlates with b-catenin protein expression in AML blasts. (a) Representative western blot images
demonstrating the localization of g-catenin and b-catenin (b-Cat) protein within normal CD34þ HSPC and AML patient blasts. Protein
loading and fraction purity were assessed by actin and histone H1 detection. (b) Summary data showing the correlation between total
g-catenin protein and total b-catenin protein in AML blasts (n¼ 59; arbitrary densitometric units). (c) Summary data showing the correlation
between cytosolic levels of b-catenin and the corresponding level of nuclear b-catenin protein in AML blasts (n¼ 59; arbitrary densitometric
units).
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(Figure 4). This contrasts with normal cells and suggests that in
most leukemia cells the mechanisms preventing nuclear localiza-
tion of g-catenin have been disturbed. These data also support our
observations in primary AML (above) showing a link between the
level of expression and nuclear localization. Examination of the
effects on b-catenin expression showed that in each case,
except HEL cells, overexpression of g-catenin also promoted
the stabilization of b-catenin. This is again consistent with the
observations of AML blasts and highlights a further abnormality of
leukemic cells, because in normal HSPC, g-catenin overexpression
did not inﬂuence b-catenin expression. As with g-catenin,
stabilization of b-catenin in AML cells tended to promote its
nuclear localization (the principal exception being U937 cells
where nuclear localization of both catenins was not detected).
To investigate whether nuclear localization of g-catenin might
be promoting b-catenin transcription, we examined whether
g-catenin overexpression inﬂuenced b-catenin mRNA levels in
these cells. Comparison of b-catenin mRNA expression between
control and g-catenin-transduced cell lines showed no change in
b-catenin mRNA levels (data not shown). This was in agreement
with our analysis of AML patients and suggested that the
stabilization of b-catenin was mediated through a post-transcrip-
tional mechanism. In support of this, we found that b-catenin
levels were acutely sensitive to the GSK inhibitor, BIO, implying
rapid turnover of this protein in leukemia cell lines
(Supplementary Figure S4).
Together, these data suggest that AML cells can differ in two
respects compared with normal cells. First, that expression of
g-catenin promotes the stabilization of b-catenin and second, that
the stabilization of catenins also leads to their nuclear
translocation.
g-Catenin overexpression promotes TCF transcription both
directly, and indirectly through b-catenin stabilization
The data above predict that overexpression of g-catenin will
promote TCF-mediated transcription in leukemia cells, which
respond through coordinate stabilization of b-catenin expression
and nuclear localization of both catenins. To investigate this,
we examined the consequence of catenin dysregulation on
TCF-dependent transcription in K562, THP-1 and also U937 cells
(which retained the resistance to catenin translocation character-
istic of normal cells). To accomplish this, these cells were
transduced with the pBARVUbR lentiviral construct, which reports
TCF transcription through expression of Venus EYFP. As shown in
Figure 5, no cell line examined demonstrated signiﬁcant
endogenous TCF reporter activity compared with control (reporter
incorporating mutant TCF sites). However, overexpression of
g-catenin in K562 and THP-1 cells signiﬁcantly promoted reporter
expression 4.5- and 3.9-fold over control cells, respectively (Figures
5a, b and d). As expected, overexpression of g-catenin in U937
cells gave no detectable response relative to controls (Figures 5c
and d), reﬂecting the resistance of these cells to catenin
translocation despite their cytosolic stabilization (Figure 4).
These data showed that, as predicted, nuclear translocation of
catenins was able to promote TCF-dependent transcription;
however, it remained unclear whether the effect of g-catenin on
TCF activity was direct or indirect through its stabilization of
b-catenin. To address this, we used lentiviral small hairpin RNA to
inhibit b-catenin expression in K562 cells overexpressing g-catenin
(which displayed the largest shift in reporter activity; Figure 5d).
Western blotting conﬁrmed that nuclear b-catenin was reduced
below control levels in these cells, whereas g-catenin expression
remained largely unaffected (Figure 6a). We then examined the
effect of b-catenin knockdown on reporter gene expression. We
found that, TCF reporter activity was signiﬁcantly reduced (by
66%) but not entirely ablated upon b-catenin knockdown (Figures
6b and c). These data indicate that g-catenin acts both directly and
indirectly (through stabilization of b-catenin) to promote
TCF-dependent transcription in hematopoietic cells.
DISCUSSION
This study is the ﬁrst to demonstrate dysregulated g-catenin
protein expression in AML or indeed in any hematological
malignancy, with 18% of patient samples exhibiting over-
expression. Though overexpression of g-catenin mRNA has been
previously reported,21,23 this had a minor contribution to protein
overexpression in our study, suggesting that post-translational
mechanisms are dominant in driving overexpression. Discordance
with mRNA has been previously reported in a variety of other
contexts for both g-32–34 and b-catenin14,16,35 and is consistent
with the view that their expression is principally regulated through
the activity of (and their susceptibility to) the destruction
complex.24 Mutations affecting these factors are the principal
drivers of b-catenin overexpression in epithelial cancers;1
however, such mutations have not been identiﬁed in
hematopoietic malignancies, suggesting that alternative
mechanisms are responsible. Here we demonstrate that
overexpression of g-catenin is able to fulﬁll that role in myeloid
leukemia. g-Catenin expression correlated with b-catenin
expression in AML blasts, and ectopic expression of g-catenin
was able to stabilize b-catenin expression in a variety of myeloid
leukemia cell lines. The mechanism driving overexpression of
g-catenin has not currently been resolved but is likely to be
multifactorial. Though mRNA levels correlated poorly with protein
level overall, they did appear to be inﬂuential in some patients. In
other tissues, previous reports have indicated that g-catenin can
be stabilized through increased ser/thr phosphorylation,36 though
without suitable antibodies this is difﬁcult to establish in primary
Figure 4. g-Catenin overexpression promotes b-catenin stabilization and translocation in leukemic blasts, but not in normal hematopoietic
cells. Representative western blot data showing the subcellular expression of g-catenin and b-catenin in normal CD34þ HSPC and myeloid
leukemia cell lines transduced with either empty vector (Cont) or g-catenin. Arrows summarize the effect of g-catenin overexpression on
cytosolic and nuclear levels of g- and b-catenin. Protein loading and fraction purity are indicated by actin and histone H1.
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material. The costabilization of b-catenin has been reported
previously in other contexts and has been proposed to arise
through competitive inhibition of the destruction complex, given
that g-catenin is less efﬁciently degraded than b-catenin.24,37
This alone may be an insufﬁcient explanation, however, given that
this costabilization of b-catenin was not detectable in normal cells.
Thus, in addition to g-catenin overexpression, the costabilization
of b-catenin by g-catenin is also an abnormal feature of AML
blasts.
A further abnormality demonstrated by AML cells was the
degree of nuclear translocation of both catenins. Overexpression
of catenins alone is insufﬁcient to promote their transcriptional
activity, which requires their translocation and retention in
the nucleus. According to the standard model of canonical
Wnt signaling, cytosolic stabilization of catenins is sufﬁcient to
promote their translocation and this was indeed seen for both
AML blasts and the majority of cell lines examined. It is clear from
our data, however, that this represents an aberration of AML cells
because normal cells do not show nuclear accumulation of
g-catenin when overexpressed. Similarly, stabilization of b-catenin
through inhibition of the destruction complex in HSPC also fails to
promote its nuclear localization (Supplementary Figure S4). HSPC
do not therefore adhere to the standard model, suggesting that
an additional level of regulation exists in hematopoietic cells that
restricts the nuclear translocation of catenins. Given the evidence
that high levels of canonical Wnt signaling are deleterious
to HSC,38 this additional level of regulation may be necessary to
protect self-renewal capacity. Evidently, this is not the case for
most AML blasts and cells lines, which either tolerate or beneﬁt
from high levels of nuclear catenin. Interestingly, one of the cell
lines examined (U937) retained the resistance to nuclear
accumulation of catenin displayed by normal cells; similarly,
Figure 3c shows a subgroup of patients with comparatively high
Figure 5. g-Catenin overexpression promotes TCF/LEF-mediated
transcription in leukemic cells. (a, b, c) Representative flow
cytometric histograms showing TCF reporter activity (Venus EYFP)
in control (Cont TCF) or g-catenin-transduced (g-Cat TCF) K562,
THP-1 and U937 cells. Autofluorescence levels (Autofluor.) were
established using parental cells. Background fluorescence arising
from construct integration is indicated by control cells transduced
with an identical construct bearing mutated TCF-binding sites
(Mutant TCF). (d) Summary data showing the relative Venus EYFP
intensity obtained from control or g-catenin-transduced K562, THP-1
and U937 cell lines. Data represents mean±1 s.d., n¼ 3. Statistical
significance is denoted by wPo0.01 and zPo0.05, as analyzed by
Student’s t-test.
Figure 6. g-Catenin promotes TCF/LEF-mediated transcription in
leukemic cells both directly and indirectly through stabilization of
b-Cat. (a) Representative western blot showing the expression and
localization of g- and b-catenin protein in K562 cells transduced with
empty vector (Cont), g-Catenin or g-catenin together with b-catenin
small hairpin RNA (g/b-Cat KO). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and histone H1 demonstrate relative
protein loading and fraction purity. (b) Representative flow
cytometric histograms showing TCF reporter activity in K562 cell
lines. (c) Summary data showing the background-subtracted TCF
reporter signal (n¼ 3). Data represents mean±1 s.d. Statistical
significance is denoted by wPo0.01 and zPo0.05, as analyzed by
Student’s t-test.
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cytosolic b-catenin levels but with undetectable nuclear expres-
sion, again indicating that loss of translocational control of
catenins is not a universal feature of AML. The movement of large
proteins, such as catenins, requires active transport across the
nuclear membrane. Both b- and g-catenin lack nuclear localiza-
tion/export signals39 and do not depend on importins or
karyopherins for nuclear translocation.40 A large number of
proteins have been implicated in the nuclear transport and
retention of catenins, including LEF-1,37 TCF4,41 APC39
and FoxM1,42 but their involvement is highly context-dependent
and the processes mediating nuclear localization of catenins are
generally poorly understood. In the hematopoietic context, it
has been reported that FLT3-ITD may promote translocation of
b-catenin through tyrosine phosphorylation at Y654.43,44 We were
unable to conﬁrm an association between FLT3-ITD and nuclear
localization of b-catenin in our patient cohort (9/39 FLT3-ITD
patients P¼ 0.75). We also found no association between Y654
phosphorylation and b-catenin nuclear localization in our cell line
panel (data not shown). Whatever the mechanisms controlling
nuclear localization of catenins, it is likely that these are at least
partly shared between g- and b-catenin because all the leukemic
cell lines assayed, and the majority of AML patient samples,
demonstrated concurrent translocation of these catenins.
The coordinated localization of these proteins to the nucleus
has previously been observed in other contexts.37,45
The coordinate translocation of each catenin raised the issue
of what role nuclear localization of g-catenin might have in
TCF-dependent transcriptional activation. Previous studies in
epithelial cells have indicated that g-catenin can activate
transcription, though with less efﬁciency than b-catenin.37,45–50
Studies have also shown that g-catenin is transcriptionally active
on b-catenin null backgrounds.45,46,51 In this study, selective
knockdown of b-catenin in g-catenin-overexpressing cells showed
that g-catenin contributes both directly and indirectly (through
stabilization of b-catenin) to promote TCF-dependent
transcription myeloid leukemia cells. Functionally, g-catenin has
been shown to promote self-renewal and leukemia in mouse
HSC22 (properties that have also been attributed to b-catenin52).
Though the corresponding effects on b-catenin expression were
not reported in these studies, our data suggest that the effects of
g-catenin overexpression could be mediated, at least in part,
through stabilization of b-catenin.
In summary, this study has identiﬁed three key abnormalities
associated with canonical Wnt signaling in AML: the overexpres-
sion of g-catenin, the costabilization of b-catenin and the
permissive nuclear localization of both catenins. These abnorm-
alities combine to promote TCF-dependent transcription in AML
and stand in contrast to catenin regulation in normal cells, which
appear to be regulated to strongly resist high levels of Wnt
signaling. Further investigations are now required in order to
elucidate the mechanisms regulating catenin nuclear transport in
normal and leukemic cells, which could be of therapeutic interest.
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